Amgen Reacquires Rights to Oncology and Bone Health Drugs

Amgen says it has reached an agreement with GSK to reacquire its remaining rights to oncology and bone health drugs.

The company will buy back from GSK rights to bone drugs Prolia (denosumab) and Xgeva (denosumab), as well as cancer therapy Vectibix (panitumumab) in 48 countries.

GSK has held selective regional rights to Prolia and Xgeva since 2009 and to Vectibix since 2010 under a licensing agreement with Amgen. In 2014, the combined licenses generated sales of about $111 million.